December 7, 2022
Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Resolian Bioanalytics Pty, Ltd., in Brisbane, Australia.
The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioanalytical support.
“Resolian’s expanded presence in Australia affirms our commitment to combining scientific talent and technology to deliver global drug development solutions,” said Resolian CEO, Patrick Bennett. “In this new purpose-built laboratory, our talented teams will use their diverse experience and expertise to provide high quality bioanalytical services.”
“Our new state-of-the-art science facility in Brisbane will further strengthen our global bioanalytical capabilities. It will allow biotech companies to work with us in Australia in the early phase and then transfer the knowledge on these assays to other regions to support the later development phases. Our objective is to accelerate the growth of our best-in-class portfolio and deliver industry-leading drug development service for our worldwide clients,” said Resolian Site President, Australia, Jason (Hao) Wang, Ph.D.
